Sorafenib treatment activates the CXCR4/SDF-1α axis, exacerbating hypoxia in HCC. This activation promotes tumor progression, invasion, metastasis, and immunosuppression, ultimately increasing resistance to sorafenib. Here, CXCR4 is linked to neoplasm.